title: [Antiplatelet therapy in 2005].
abstract: Atherothrombosis is a common physiopathologic process resulting in morbid or fatal ischemic events affecting the cerebral, coronary, or peripheral arterial circulation. Antiplatelet agents are effective in preventing recurrence of vascular events among patients with established vascular disease or with multiple risk factors. Aspirin was the most widely studied antiplatelet drug but the optimal dose remains difficult to define. This article summarizes new data on antiplatelet agents including aspirin, clopidogrel, dipyridamole and glycoprotein IIb/IIIa antagonists with the aim of giving practical recommendations in this very moving field of therapy.
authors.affiliation: Service de Pathologie Vasculaire, Hôpital Erasme, Bruxelles.
authors.forename: J C
authors.initials: JC
authors.lastname: Wautrecht
authors.forename: J
authors.initials: J
authors.lastname: Sternon
mesh_terms: D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors